Journal Article
Review
Add like
Add dislike
Add to saved papers

The Role of Toll Like Receptors (TLRs) in Oral Carcinogenesis.

Anticancer Research 2017 October
Oral cancer accounts for 10% of head and neck tumors. Despite the recent advancements in surgical techniques, as well as in chemo- and radiotherapy therapeutic protocols, survival rates for oral cancer patients have not improved significantly in the last decades. Recently, toll like receptors (TLRs) have been described as promoters of cell proliferation, invasiveness, and angiogenesis in a variety of cancers. The aim of this review is to identify how TLRs participate in oral carcinogenesis in order to evaluate their biological relevance. Data revealed that some TLRs participate in oral carcinogenesis since TLR5 and TLR9 promote tumor growh, whereas TLR3 is closely involved to anti-cancer properties. They represent a promising alternative for oral cancer therapy. However, TLR2, TLR4 and TLR7 need further investigation, since current data are not sufficient to conclude about their role. Certainly, such data will contribute to new scientific knowledge, which will be incorporated to the preventive actions and therapeutic protocols for oral cancer patients suffering from this devasting disease.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app